PubRank

John Yarnold

Author PubWeight™ 32.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009 2.75
2 Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007 2.32
3 TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005 1.78
4 Effect of breast-duct anatomy and wound-healing responses on local tumour recurrence after primary surgery for early breast cancer. Lancet Oncol 2009 1.44
5 Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 2010 1.23
6 Accelerated partial breast irradiation trials: diversity in rationale and design. Radiother Oncol 2009 1.09
7 Haste makes waste: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat 2014 1.07
8 Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol 2002 1.04
9 Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy. Radiother Oncol 2011 0.98
10 Planning with intensity-modulated radiotherapy and tomotherapy to modulate dose across breast to reflect recurrence risk (IMPORT High trial). Int J Radiat Oncol Biol Phys 2010 0.98
11 Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 2006 0.94
12 Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiother Oncol 2004 0.92
13 Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 2012 0.91
14 Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials. Radiother Oncol 2013 0.90
15 Evaluation of implanted gold seeds for breast radiotherapy planning and on treatment verification: a feasibility study on behalf of the IMPORT trialists. Radiother Oncol 2011 0.88
16 Test of association between variant tgβ1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol 2010 0.88
17 Large breast size as a risk factor for late adverse effects of breast radiotherapy: is residual dose inhomogeneity, despite 3D treatment planning and delivery, the main explanation? Radiother Oncol 2011 0.88
18 Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy. Radiother Oncol 2013 0.87
19 Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res 2006 0.86
20 Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. Radiother Oncol 2005 0.86
21 Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol 2004 0.86
22 Variation in the manganese superoxide dismutase gene (SOD2) is not a major cause of radiotherapy complications in breast cancer patients. Radiother Oncol 2002 0.83
23 DNA double-strand break repair and induction of apoptosis in ex vivo irradiated blood lymphocytes in relation to late normal tissue reactions following breast radiotherapy. Radiat Environ Biophys 2014 0.83
24 Guidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8(th) Annual Women's Cancer Initiative - Tata Memorial Hospital (WCI-TMH) Conference. Indian J Med Paediatr Oncol 2012 0.82
25 Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer. Radiother Oncol 2010 0.82
26 Correlation of in vitro lymphocyte radiosensitivity and gene expression with late normal tissue reactions following curative radiotherapy for breast cancer. Radiother Oncol 2012 0.82
27 Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. Radiother Oncol 2006 0.81
28 Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skin. Radiother Oncol 2011 0.81
29 The relationship between homologous recombination repair and the sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy. Clin Cancer Res 2012 0.81
30 Dynamic MRI of breast hardness following radiation treatment. J Magn Reson Imaging 2003 0.78
31 The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy. Radiother Oncol 2012 0.78
32 Double-blind randomised phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiother Oncol 2005 0.75